Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
5.73
+0.12 (2.14%)
At close: Mar 12, 2025, 4:00 PM
5.72
-0.01 (-0.26%)
After-hours: Mar 12, 2025, 4:18 PM EST
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
444.03M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SLDB News
- 9 hours ago - Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewsWire
- 6 days ago - Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 days ago - Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 8 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data - Benzinga
- 22 days ago - Solid Biosciences Announces Pricing of Underwritten Offering - GlobeNewsWire
- 22 days ago - Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 - GlobeNewsWire
- 7 weeks ago - Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart - Seeking Alpha